An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de Hierro phase I/II clinical trial

Cytotherapy cover

Personalized cell therapy with MSCs is safe and leads to clear improvements in clinical aspects and quality of life for patients with complete and chronically established paraplegia.

Source: Summary of Website

Identification

Category: 

Document type: 

Research

Tomo/Volumen: 

18

Issue: 

8

ISBN/ISSN/NIPO: 

ISSN 1465-3249
Terms
Bibliographic data
Additional Information

Source: 

AT Observatory